A Pilot Study of Berberine (Soloways ™) in Patients with Type 2 Diabetes Mellitus Carrying TCF7L2 Polymorphisms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-03

Study Completion Date

2024-10-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot, genotype-stratified clinical trial aims to investigate the safety and preliminary efficacy of berberine supplementation in adult patients with type 2 diabetes mellitus (T2DM) who carry a specific high-risk TCF7L2 polymorphism (e.g., rs7903146) in the homozygous state. The study will compare improvements in glycemic control and metabolic markers between two groups: (1) homozygous carriers of the TCF7L2 "unfavorable" variant and (2) non-carriers (wild-type). It is hypothesized that berberine will yield greater reductions in HbA1c and fasting plasma glucose among homozygous carriers, potentially due to their distinct TCF7L2-mediated insulin secretion and sensitivity pathways.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes Patients

NCT06313164

Type 2 Diabetes

COMPLETED NA

Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study

NCT03976336

Metabolic Syndrome

COMPLETED NA

Berberine and Cinnamon in Management of Diabetes

NCT05570357

Diabetes

COMPLETED NA

Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects

NCT06422039

Type 2 Diabetes Mellitus

NOT_YET_RECRUITING PHASE1

Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets in Type-2 Diabetes Mellitus Patients

NCT06961019

Type2 Diabetes Mellitus

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 diabetes mellitus is driven by a combination of insulin resistance and impaired insulin secretion. Genetic polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene have been strongly associated with an increased risk of T2DM, potentially through altered beta-cell function and incretin signaling. Berberine, a natural alkaloid derived from plants such as Coptis chinensis, has demonstrated hypoglycemic effects by modulating pathways like AMPK, thereby improving insulin sensitivity and glucose metabolism. This pilot trial aims to clarify whether berberine offers a more pronounced metabolic benefit to individuals homozygous for a "high-risk" TCF7L2 polymorphism by targeting their unique pathophysiological mechanisms. Results will inform future larger-scale, genotype-focused interventional trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TCF7L2 Homozygous Variant Cohort

Group Type EXPERIMENTAL

Berberine

Intervention Type DIETARY_SUPPLEMENT

Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care

Non-Variant (Control) Cohort

Group Type ACTIVE_COMPARATOR

Berberine

Intervention Type DIETARY_SUPPLEMENT

Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Berberine

Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care

Intervention Type DIETARY_SUPPLEMENT

Berberine

Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (age 30-70 years) with a confirmed diagnosis of type 2 diabetes mellitus.
* On stable doses of metformin or other standard oral antihyperglycemic agents for at least 4 weeks prior to enrollment.
* Willingness to undergo genetic testing for TCF7L2 polymorphisms. For the Homozygous Variant Cohort: confirmed homozygous high-risk TCF7L2 polymorphism (e.g., rs7903146) prior to enrollment.
* For the Non-Variant Cohort: confirmed wild-type TCF7L2 genotype.

Exclusion Criteria

* Current use of insulin therapy or recent (within 4 weeks) change in diabetic medications.

Known hypersensitivity or intolerance to berberine or related compounds.

* Significant renal or hepatic impairment.
* Pregnancy or breastfeeding.
* Any other acute or chronic condition that, in the investigator's judgment, could compromise the patient's safety or the study's integrity.

Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No